Sign In
Buy SAN
$12.47
+0.310 (+2.55%)
At Close: Jun 04, 2026
Santander withdraws bidding for Citi’s Banamex
07:39am, Friday, 22'nd Jul 2022 MarketWatch
The Spanish bank said it had submitted a non-binding offer for the unit, but it won't be continuing in the next stages of the process, Santander said in a statement.
Analyst says Santander's exit from Banamex bidding may ease capital concerns
07:19am, Friday, 22'nd Jul 2022
Jefferies analyst Benjie Creelan-Sandford said Friday the confirmation from Banco Santander S.A. SAN, +1.64% that it won't continue bidding for Citigroup Inc.'s C, +0.27% Banamex unit in Mexico should
Santander says is out of Citigroup's sale of Citibanamex
02:27am, Friday, 22'nd Jul 2022
Spain's Santander said on Friday it was out of the process to buy Citigroup's Mexican unit.
Sanofi: Information concerning the total number of voting rights and shares – June 2022
04:52pm, Wednesday, 20'th Jul 2022 GlobeNewswire Inc.
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement
Sanofi: Informations relatives au nombre de droits de vote et d'actions – JUIN 2022
04:52pm, Wednesday, 20'th Jul 2022 GlobeNewswire Inc.
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marc
Santander bank's former Midtown office tower scooped up
12:23pm, Sunday, 17'th Jul 2022
We first reported on the pending acquisition from Florida-based MEK Management Services in April.
Press Release: Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis
05:00am, Thursday, 14'th Jul 2022 GlobeNewswire Inc.
Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis
Communiqué de presse: Résultats positifs de phase III pour Dupixent® (dupilumab) dans le traitement de l’œsophagite à éosinophiles de l’enfant âgé de 1 à 11 ans
05:00am, Thursday, 14'th Jul 2022 GlobeNewswire Inc.
Résultats positifs de phase III pour Dupixent® (dupilumab) dans le traitement de l’œsophagite à éosinophiles de l’enfant âgé de 1 à 11 ans
Is WisdomTree Europe Hedged Equity ETF (HEDJ) a Strong ETF Right Now?
10:20am, Wednesday, 13'th Jul 2022 Zacks Investment Research
Smart Beta ETF report for HEDJ
Santander Hedged And Ready For Higher Rates
08:00am, Wednesday, 13'th Jul 2022
Santander is hedged and ready for higher rates compensating for their high proportion of fixed-rate loans. The bank has a nice dividend yield at 3.8%, which including buybacks brings the total capital
Press Release: Pivotal data demonstrate once-weekly efanesoctocog alfa provides superior bleed protection compared to prior factor prophylaxis
01:45pm, Sunday, 10'th Jul 2022 GlobeNewswire Inc.
Pivotal data demonstrate once-weekly efanesoctocog alfa provides superior bleed protection compared to prior factor prophylaxis
Press Release: Fitusiran prophylaxis reduced bleeds by 61% in people with hemophilia A or B, with or without inhibitors, compared to prior factor or bypassing agent prophylaxis
01:45pm, Sunday, 10'th Jul 2022 GlobeNewswire Inc.
Fitusiran prophylaxis reduced bleeds by 61% in people with hemophilia A or B, with or without inhibitors, compared to prior factor or bypassing agent prophylaxis
Des données pivots démontrent que l’efanesoctogog alpha une fois par semaine confère une protection supérieure contre les saignements, comparativement à une prophylaxie antérieure par facteur
Une prophylaxie par fitusiran a réduit de 61 % les saignements chez les personnes atteintes d’hémophilie A ou B, avec ou sans inhibiteurs, comparativement à une prophylaxie antérieure par facteu
NextEnergy Solar Fund agrees 2-year extension to £70mln Santander credit facility
02:36am, Tuesday, 05'th Jul 2022
NextEnergy Solar Fund Ltd (LSE:NESF) (NESF) has extended its £70mln credit facility with Santander UK by two years, allowing it to take advantage of investment opportunities in the renewable energy s
